SHALBY.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 12:59):

Stats
Šios dienos apimtis	269 841
Vidutinė apimtis	271 325
Rinkos kapitalizacija	30.22B
EPS	INR0 ( 2024-02-12 )
Kita pelno data	( INR0 ) 2024-05-12
Last Dividend	INR1.200 ( 2023-08-08 )
Next Dividend	INR0 ( N/A )
P/E	36.91
ATR14	INR0.454 (0.16%)

Tūris Koreliacija

Ilgas: -0.12 (neutral)

Trumpas: -0.92 (very strong negative)

Signal:(50.528) Neutral

Shalby Limited Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Shalby Limited Koreliacija - Valiuta/Žaliavos

0.01
( neutral )

0.24
( neutral )

-0.32
( neutral )

0.09
( neutral )

0.18
( neutral )

-0.32
( neutral )

Shalby Limited Finansinės ataskaitos

Annual	2022
Pajamos:	INR8.05B
Bruto pelnas:	INR3.70B (45.94 %)
EPS:	INR6.30

FY	2022
Pajamos:	INR8.05B
Bruto pelnas:	INR3.70B (45.94 %)
EPS:	INR6.30

FY	2022
Pajamos:	INR6.99B
Bruto pelnas:	INR3.05B (43.58 %)
EPS:	INR6.46

FY	2021
Pajamos:	INR4.31B
Bruto pelnas:	INR1.81B (42.07 %)
EPS:	INR4.71

Financial Reports:

No articles found.

Shalby Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR1.000 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR1.200 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Shalby Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 3.43 - low (14.10%) | Divividend Growth Potential Score: 4.23 - Stable (15.37%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.500	2019-08-16
Last Dividend	INR1.200	2023-08-08
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	INR4.20	--
Avg. Dividend % Per Year	0.51%	--
Score	1.9	--
Div. Sustainability Score	3.43
Div.Growth Potential Score	4.23
Div. Directional Score	3.83	--

Next Divdend (Est)
(2024-07-01)

INR1.377 Estimate 3.09 %

Dividend Stability

0.25 Very Poor

Dividend Score

1.90

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2019	INR0.500	0.34%
2020	INR0.500	0.54%
2021	INR1.000	0.92%
2022	INR1.000	0.70%
2023	INR1.200	0.79%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
RELAXO.NS	Dividend Junior	2023-08-17	Annually	14	0.17%
KRBL.NS	Dividend Junior	2023-08-25	Annually	23	0.61%
FCL.NS	Dividend Junior	2023-09-08	Annually	10	0.22%
ANANTRAJ.NS	Dividend Junior	2023-06-27	Annually	18	0.22%
TATACOFFEE.NS	Dividend Junior	2023-05-15	Annually	23	0.85%
NIACL.NS	No Dividend Player	2023-09-07	Sporadic	7	0.44%
INDIAGLYCO.NS	Dividend Junior	2023-09-05	Sporadic	20	0.85%
CHOLAHLDNG.NS	Dividend Junior	2023-08-03	Annually	23	0.06%
SANDHAR.NS	Dividend Junior	2023-09-14	Annually	7	0.66%
LXCHEM.NS	Dividend Junior	2023-07-20	Annually	4	0.11%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0916	1.500	8.17	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.0860	1.500	-0.155	-0.233	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	10.77	1.000	7.12	7.12	[3 - 30]
operatingCashFlowPerShareTTM	6.92	2.00	7.69	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.92	2.00	6.54	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.464	1.000	5.60	5.60	[0.2 - 0.8]
operatingProfitMarginTTM	0.150	1.000	9.00	9.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.43

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	36.82	1.000	6.38	0	[1 - 100]
returnOnEquityTTM	0.0860	2.50	-0.0997	-0.233	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.92	2.00	7.69	10.00	[0 - 30]
dividendYielPercentageTTM	0.429	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.92	2.00	7.69	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	1.340	1.500	4.40	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0834	1.000	-0.415	0	[0.1 - 0.5]
Total Score				4.23

Shalby Limited

Shalby Limited operates multi-specialty hospitals primarily in India. The company offers arthroscopy, arthroplasty, cardiology, cardiothoracic and vascular surgery, cosmetic and aesthetic, dental cosmetic and implant ology, emergency medicine, endocrinology, endoscopy and laparoscopy, ENT surgery, gastroentero surgery, gastroenterology, general medicine and surgery, hair transplant, liver disease and transplant, and hip and knee joint replacement services. It also provides infectious disease, infertility and IVF, intensive and critical care, maxillofacial surgery, nephrology, neuro surgery, neurology, obesity surgery, obstetrics and gynecology, oncology, oncosurgery, ophthalmology and glaucoma, orthopedic and trauma, pediatric orthopedic, pathology and microbiology, pediatrics and neonatology, plastic surgery, pulmonology and chest, radiology and imaging, rheumatology, trauma, organ donation, and urosurgery services. The company operates 11 hospitals comprising aggregate capacity of 2,012 beds. In addition, it offers outpatient services through 50 outpatient clinics, as well as provides educational programs and fellowships for paramedical students and other healthcare professionals; and homecare health services, such as attendants, doctors, nursing, physiotherapy, pathology, pharmacy, and medical equipment, as well as conducts clinical research trials. It also operates in Kenya, Tanzania, Rwanda, Uganda, the United Arab Emirates, Bangladesh, Cambodia, Jakarta, Oman, Uzbekistan, Nepal, and internationally. The company was formerly known as Shalby Hospitals Limited and changed its name to Shalby Limited in February 2008. Shalby Limited was founded in 1994 and is headquartered in Ahmedabad, India.